About Us
Abivax is developing therapies that modulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat chronic inflammatory diseases, viral diseases, and cancer.
Its lead clinical candidate, obefazimod, has demonstrated strong clinical anti-inflammatory effects in ulcerative colitis.
Pipeline
With four programs in clinical testing, a trial in Crohn’s disease to start and three projects in research and preclinical development, Abivax’s pipeline is strong and diversified, addressing many unmet needs.
Clinical Programs
-
Obefazimod UC
Obefazimod is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in Phase 2a and Phase 2b induction trials to treat ulcerative colitis (UC). Patients who completed the induction studies had the option to roll over into the respective open-label extension studies.
Read More -
Obefazimod Rheumatoid Arthritis
Obefazimod is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in the completed Phase 2a and Phase 2b induction studies as well as in long-term maintenance studies in patients with moderate-to-severe ulcerative colitis (UC) and rheumatoid arthritis (RA). In addition to the clinical observations in UC patients, Abivax generated excellent phase 2a clinical results in the RA induction and subsequent maintenance study after one year of treatment.
Read More -
ABX196 HCC
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer models.
Read More -
Obefazimod Crohn’s Disease
Obefazimod is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in the completed Phase 2a and Phase 2b induction studies as well as in ongoing long-term maintenance studies in patients with moderate-to-severe ulcerative colitis (UC).
Read More
Due to the clinical similarities of Crohn’s disease (CD) and UC, and the predictability of the DSS model for both UC and CD, several key opinion leaders (KOLs) are confident that obefazimod will also show beneficial effects in patients suffering from CD.
R&D Assets

Science
Based on innovative research driven by the idea of modulating the body’s natural immune system mechanisms to cure diseases.

Investors
Abivax SA has been listed on the Paris stock exchange since June 26, 2015.
Symbol
ABVX
